34 research outputs found

    The Oral Health Status of Patients with Peripheral Vascular Disorders : A Systematic Review

    Get PDF
    The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: SAA was funded by the NHS Grampian Vascular Surgery Department, and MM was funded by the University of Aberdeen Institute of Dentistry through the Aberdeen Summer Research Scholarship as part of the Aberdeen Clinical Academic Training (ACAT).Peer reviewedPublisher PD

    Introducing endovenous laser therapy ablation to a national health service vascular surgical unit e the aberdeen experience

    Get PDF
    Objectives: To report early clinical outcomes and learning experience following the introduction of endovenous laser ablation (EVLA) to an NHS vascular unit. Design: Prospective observational study. Results: Between February 2006 and January 2008, 631 consecutive patients underwent EVLA to 704 refluxing truncal veins e 579 GSV, 119 SSV and 6 straight segments of anterior accessory GSV. 275/631 (44%) patients had local anaesthesia (LA) plus sedation, 237 (38%) had LA only and 119 (18%) had general anaesthesia. All were treated using the 810 nm diode laser. Adjuvant procedures on-table included foam sclerotherapy 129/704 (18%), multiple stab avulsions 53/ 704 (8%) and 3 limbs had both. Three-month follow-up with duplex examination is complete in 635/704 limbs (90%). Complete occlusion was noted in 610 veins (96%), 14 (2.2%) were partially occluded and 11 (1.7%) showed no occlusion. 193 (30%) of the 635 limbs seen at follow-up required further treatment for residual varicosities using foam sclerotherapy. There has been one non-fatal pulmonary embolus associated with EVLA and no other complications. Conclusions: EVLA is safe and technically effective. It has a defined learning curve requiring new operator skills which can be readily acquired.peer-reviewe

    Randomized clinical trial of the antiplatelet effects of aspirin–clopidogrel combination versus aspirin alone after lower limb angioplasty

    Get PDF
    There is a high risk of reocclusion after successful lower limb angioplasty. Platelets play a central role in this process. The aim of this study was to investigate the antiplatelet effect of a combination of aspirin and clopidogrel compared with aspirin alone in patients with claudication undergoing endovascular revascularization. Methods This was a double-blind randomized placebo-controlled trial. Some 132 patients were randomized to clopidogrel and aspirin or placebo and aspirin, with a loading dose 12 h before endovascular intervention. Flow cytometric measurements of platelet fibrinogen binding and P-selectin expression were taken as measures of platelet function at baseline, 12 h after the loading dose, and 1 h, 24 h and 30 days after intervention. Results Within 12 h of the loading dose, platelet activation in the clopidogrel group had decreased (P-selectin by 27·3 per cent, P = 0·017; fibrinogen binding by 34·7 per cent, P = 0·024; stimulated fibrinogen binding by 49·2 per cent, P < 0·001). No change was observed in the placebo group. Platelet function in the clopidogrel group was significantly suppressed compared with baseline at 1 h, 24 h and 30 days after endovascular intervention (stimulated fibrinogen binding by 53·9, 51·7 and 57·2 per cent respectively; all P < 0·001). Conclusion A combination of clopidogrel and aspirin inhibited platelet function more than aspirin alone in patients with claudication before and after angioplasty.peer-reviewe

    Platelet activation is increased in peripheral arterial disease

    Get PDF
    Platelet activation was assessed in patients with peripheral arterial disease compared with healthy control subjects. Methods This prospective comparative study included 100 subjects: 40 consecutive patients with intermittent claudication, 20 consecutive patients with critical ischemia and tissue loss, and 40 healthy control subjects. Whole blood flow cytometric analysis was performed to determine resting and stimulated platelet P-selectin expression and resting and stimulated platelet fibrinogen binding. Results are presented as platelet percentage and also as mean fluorescence intensity. Results P-selectin expression was significantly increased in patients with intermittent claudication (median, 0.85%; range, 0.31%-4.77%; P = .023) and critical ischemia (median, 1.11%; range, 0.2%-3.26%; P = .028) compared with control subjects (median, 0.59%; range, 0.16%-4.58%). The percentage of platelets binding fibrinogen was also significantly higher in patients with intermittent claudication (median, 2.89%; range, 1.08%-9.59%; P < .001) compared with control subjects (median, 1.57%; range, 0.17%-10.7%). There was no significant difference in percentage of platelet fibrinogen binding between control subjects and patients with critical ischemia. Fibrinogen binding by stimulated platelets was significantly diminished in patients with critical limb ischemia compared with control subjects (67.2% vs 77.9%; P = .006). Conclusions Platelet activation is increased in patients with peripheral arterial disease, suggesting an underlying prothrombotic state. Platelets from patients with critical limb ischemia are less responsive to in vitro stimulation.peer-reviewe

    Clopidogrel has no effect on D-dimer and thrombin-antithrombin III levels in patients with peripheral arterial disease undergoing peripheral percutaneous transluminal angioplasty

    Get PDF
    Objective: Coagulation activation markers are significantly elevated in patients with peripheral arterial disease compared with healthy controls. The more severe the disease, the higher the markers. Increased coagulation activation may contribute to the disease process and the risk of complications in patients with peripheral arterial disease, particularly after endovascular intervention. Animal studies have shown that clopidogrel significantly inhibits coagulation activation. The aim of this study was to determine whether combination of aspirin and clopidogrel affects thrombin-antithrombin III and D-dimer in patients with intermittent claudication undergoing angioplasty, compared with aspirin alone. Methods: This was a double blind, randomized placebo-controlled trial conducted in a vascular unit in a tertiary referral center. One hundred thirty-two patients with intermittent claudication were randomized to clopidogrel and aspirin or placebo and aspirin, with a loading dose 12 hours before endovascular intervention. D-dimer and thrombin-antithrom- bin III (TAT) levels were measured using enzyme-linked immunosorbent assay at baseline, 1 hour before, and 1 hour, 24 hours, and 30 days after intervention in 103 patients who underwent endovascular intervention. Results: There was a significant rise in D-dimer levels at 1 hour and 24 hours after angioplasty in both groups (placebo group: 63.69, 141.45, 122.18 ng/mL; clopidogrel group: 103.79, 159.95, 134.69 ng/mL), but no difference between the two groups (P .514). Similarly there was a significant rise in TAT levels at 1 hour after angioplasty in both groups (placebo group: 2.93, 6.16 g/L; clopidogrel group: 3.39, 5.27 g/L), with no significant difference between the two groups (P .746). Conclusion: Endovascular intervention results in a significant increase in TAT and D-dimer. The addition of clopidogrel to aspirin has no effect on TAT and D-dimer before or after endovascular intervention.peer-reviewe

    Markers of coagulation activation, endothelial stimulation and inflammation in patients with peripheral arterial disease

    Get PDF
    Objectives. Patients with peripheral arterial disease have a significantly increased risk of cardiovascular and cerebrovascular mortality. Studies have shown that some haemostatic and inflammatory markers are elevated in these patients but the effect of the severity of the disease has not been fully documented. The aim of this study was to assess the level of coagulation activation, endothelial stimulation and inflammation in patients with claudication and critical limb ischaemia (CLI) compared to healthy controls. Design and methods. A prospective observational study was conducted amongst 202 subjects: 132 claudicants, 30 patients with critical ischaemia, and 40 controls. D-dimer (DD) and thrombin–antithrombin III (TAT) levels measured using ELISA as markers of coagulation activation. von Willebrand factor (vWF) and high-sensitivity C-reactive protein (CRP) levels were measured as markers of endothelial and inflammatory stimulation. Results. vWF and CRP levels were significantly higher in patients with intermittent claudication (1.9 U/ml, range 0.78– 4.05; p!0.001; 3.4 mg/l, range 0.15–24; pO0.001, respectively) and critical ischaemia (2.36 U/ml; range 1.03–5.69; p! 0.001; 7.17 mg/ml, range 0.15–174; p!0.001, respectively) compared to controls (1.28 U/ml, range 0.62–3.13; 1.04, range 0.15–7.59 mg/l). DD was also significantly higher in claudicants (48.6 mg/ml; range 2–1741; p!0.001) and in patients with CLI (61.1 mg/ml, range 3.65–1963; p!0.001) compared to controls (26.1 mg/ml, range 9.65–203.1). TAT levels were significantly higher in CLI (3.14 mg/l, range 2.09–58.11), compared to controls (2.36 mg/l, range 1.49–7.38; pZ0.004). Patients with CLI had significantly higher levels of CRP, vWF, and TAT than claudicants. Conclusions. Coagulation activation and endothelial stimulation are significantly increased in patients with peripheral arterial disease compared to healthy controls. Coagulation and endothelial activation increases with the severity of the arterial disease.peer-reviewe

    Low intensity shockwave treatment modulates macrophage functions beneficial to healing chronic wounds

    Get PDF
    Acknowledgments: We acknowledge the University of Aberdeen Microscopy and Histology Facility and the qPCR facility for use of facilities and advice. We acknowledge Ehab Husain for scoring the patient wound biopsies. Funding: This research was funded by NHS Grampian Endowments, grant number 17/004 and by personal funding from JSH.Peer reviewedPublisher PD

    Double-blind randomized placebo-controlled trial of the antiplatelet effects of aspirin-clopidogrel combination versus aspirin alone at endovascular intervention for intermittent claudication of the lower limb

    Get PDF
    Intermittent claudication is a common problem which causes significant impairment of quality of life and increased mortality. Endovascular recanalization, widely used for symptomatic relief, carries a high risk of reocclusion. Platelets play a central role in this process. Aspirin currently used in claudicants reduces the risk, and more potent antiplatelet strategies may reduce this further. The aim of this study was to investigate the antiplatelet effect of aspirin–clopidogrel versus aspirin alone in patients with claudication undergoing endovascular intervention. Methods: This was a double-blind randomized placebo-controlled trial; 132 patients were randomized to clopidogrel and aspirin or to placebo and aspirin with a loading dose 12 h before endovascular intervention. Flow cytometric measurement of platelet fibrinogen binding and P-selectin expression as measures of platelet activation status and of platelet responsiveness to stimulation at baseline, 12 h post-loading dose, 1 h, 24 h and 30 days postintervention. Results: Platelet activation was significantly diminished in the clopidogrel group at 12 h post-loading dose compared to baseline (P-selectin: 27·3 per cent reduction, P = 0·017; bound fibrinogen: 34·7 per cent reduction, P = 0·024; stimulated bound fibrinogen: 49 per cent, P < 0·001). No significant change was observed in the control group. Platelet function was significantly suppressed in the clopidogrel group at 1 h, 24 h and 30 days after endovascular intervention compared to the placebo group (P < 0·001). Conclusion: Clopidogrel–aspirin combination dramatically inhibits platelet function in claudicants before and after intervention. The combination treatment may help reduce reocclusion after endovascular recanalization.peer-reviewe

    Management of secondary risk factors in patients with intermittent claudication

    Get PDF
    Objectives: the first line management of patients with intermittent claudication is "best medical therapy'' i.e., smoking cessation, exercise, antiplatelet therapy and risk factors modification. The aim of this study was to assess the current management of risk factors in primary care and to compare General Practitioner (GP) attitudes and actual management. Design and Methods: postal questionnaire of all 336 GPs in the referral area (Grampian, Scotland). Questionnaire and measurement of serum cholesterol, blood glucose and HbA1c of new clinic patients (n 104) with claudication referred by general practitioners. Results: a 73% GP response rate was obtained. Ninety-five percent of GPs would treat risk factors. The vast majority would prescribe aspirin, yet 28% of patients were on no anti-platelet therapy. Eighty-nine percent of GPs would advise an increase in exercise but only 14% of patients recalled being told to do so. One in seven of the GPs would not check serum cholesterol, 18% considered cholesterol lowering therapy to be primary prevention and 41% would only treat levels above 5.5 mmol/l. Eighty-five percent of patients were on a statin or had a cholesterol above 5 mmol/L. Seventy-seven percent of GPs would check glucose levels, and 14% of patients were found to be previously undiagnosed diabetics. Conclusions: risk factors in claudicants are suboptimally managed. Urgent guidelines for the specific management of claudicants by general practitioners, as well as strategies to ensure their implementation, are required.peer-reviewe

    Completing the audit cycle : comparison of cardiac risk factor management in patients with intermittent claudication in two time periods

    Get PDF
    Aim. The first line treatment of patients with intermittent claudication (IC) is to prolong life via cardiac risk factor management. We aimed to compare current standards of secondary prevention with those in a previously published audit. Methods. Risk factor data was prospectively collated on 304 consecutive new referrals attending the claudication clinic over a 1-year period (2004/2005) and compared to the 104 patients assessed in 2000. Results. In 2004/5 30%, (n=91) of patients did not have a diagnosis of IC confirmed (p < 0.01). The use of antiplatelet therapy remained static at 73%. Statin therapy increased in 2004/5 (62% versus 38%, p < 0.01) but blood pressure control remained poor with 65% failing to achieve the target levels. Smoking cessation therapy continues to be offered to a minority of patients and 17% of patients have previously undiagnosed diabetes in 2004/2005 (p-value 0.353). The number of patients who have been advised to increase physical activity significantly has fallen from 15% to 2% in the 2004/5 (p < 0.01). Conclusions. Difficulties exist in diagnosing intermittent claudication in primary care and cardiac risk factor manage- ment continues to be sub-optimally managed.peer-reviewe
    corecore